Compare CENT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENT | HRMY |
|---|---|---|
| Founded | 1955 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | N/A | 2020 |
| Metric | CENT | HRMY |
|---|---|---|
| Price | $33.03 | $35.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $50.00 | $49.75 |
| AVG Volume (30 Days) | 66.8K | ★ 638.0K |
| Earning Date | 02-04-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.41 | 50.44 |
| EPS | 2.55 | ★ 3.17 |
| Revenue | ★ $3,129,064,000.00 | $825,944,000.00 |
| Revenue This Year | $2.17 | $23.29 |
| Revenue Next Year | $2.13 | $15.98 |
| P/E Ratio | $12.98 | ★ $11.38 |
| Revenue Growth | N/A | ★ 21.13 |
| 52 Week Low | $28.77 | $25.52 |
| 52 Week High | $41.25 | $40.93 |
| Indicator | CENT | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 42.50 |
| Support Level | $31.41 | $34.68 |
| Resistance Level | $32.57 | $39.40 |
| Average True Range (ATR) | 0.60 | 1.25 |
| MACD | 0.05 | -0.35 |
| Stochastic Oscillator | 84.85 | 27.97 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.